Why Is Natera Stock Up Nearly 41% Since May?
Natera (NTRA) stock rose 40.8% from May 20 to November 16, 2026, driven by strong revenue growth and raised forecasts. The company reported Q2 revenue of $752.8M (up 37.7% YoY) and Q3 revenue of $794M (up 34.1% YoY), with a narrowed operating loss margin. Natera also gained in organ transplant testing due to Medicare coverage. The stock's performance outpaced the S&P 500, which gained 0.3% over the same period.
How this was made

The 30-second read
Why it matters
The piece links the rally to strong revenue growth and a higher full-year forecast, plus Medicare coverage taking effect for transplant monitoring, while emphasizing that profitability depends on operating-margin progress.
Market read
Traders get a catalyst map for Natera’s move: revenue growth, raised guidance, narrowing operating losses, and the next operating-margin inflection expected in February 2027.
What to watch
Operating margin is flagged as the next key metric, so investors may be underweighting execution risk toward profitability despite revenue growth and forecast raises.
Background
Natera sells DNA tests for cancer care, prenatal care, and organ transplants, and the article explains the stock’s ~41% rise since May alongside two quarterly updates.
Ticker impact
Natera shares surged after its Nov. 5 report raised the full-year revenue forecast to above $3B and set a 2029 $6B goal.
Near-term bias remains upward on continued execution, but volatility risk persists given the prior selloff after the second report and the next operating-margin checkpoint.
The article attributes the multi-month rally to two quarterly reports, with the Nov. 5 forecast raise as the key catalyst, while also flagging that the next report’s operating margin is the key metric.
Market effects
Reinforces investor appetite for profitable momentum in molecular diagnostics and cancer/prenatal testing, especially where reimbursement expands.
Primarily US-listed growth-stock sentiment, with limited direct regional spillover beyond healthcare diagnostics.
Moderate, as reimbursement-driven demand and margin trajectory are globally relevant themes for diagnostic providers.
Counterpoint
The article’s own timeline shows the stock jumped after the Aug. 6 report but fell after the Nov. 5 report, suggesting the market may be trading expectations rather than fundamentals.
Key entities
- companyNatera
DNA testing company whose quarterly reports and guidance changes drove the stock’s multi-month move.
- peerLabcorp
Mentioned as a comparison point for stock performance over the same period.



